PE20020486A1 - Compuestos triciclicos como inhibidores de la farnesil proteino transferasa - Google Patents
Compuestos triciclicos como inhibidores de la farnesil proteino transferasaInfo
- Publication number
- PE20020486A1 PE20020486A1 PE2001000865A PE2001000865A PE20020486A1 PE 20020486 A1 PE20020486 A1 PE 20020486A1 PE 2001000865 A PE2001000865 A PE 2001000865A PE 2001000865 A PE2001000865 A PE 2001000865A PE 20020486 A1 PE20020486 A1 PE 20020486A1
- Authority
- PE
- Peru
- Prior art keywords
- united
- compounds
- link
- farnesil
- tricyclic compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229950008696 farnesil Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 abstract 1
- -1 CHLORMETINE Chemical compound 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 230000003325 follicular Effects 0.000 abstract 1
- 229960001101 ifosfamide Drugs 0.000 abstract 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 abstract 1
- 229960000952 pipobroman Drugs 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
- 229960001055 uracil mustard Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS TRICICLICOS DE FORMULA I DONDE UNO DE a, b, c, d ES N, N+O-; EL RESTO SON C SUSTITUIDOS CON R1 O R2; SI X Y C11 ESTAN UNIDOS POR ENLACE SIMPLE, X ES N, CH; SI ENTRE X Y C11 ESTAN UNIDOS POR DOBLE ENLACE X ES C; SI C5 Y C6 ESTA UNIDOS POR ENLACE DOBLE A Y B NO SON H; SI C5 Y C6 ESTAN UNIDOS POR ENLACE SIMPLE UNO DE A Y B ES H, O A Y B SON R9, R9C0R9, (CH2)pC(R9)-OR9a, ENTRE OTROS; p ES 0-4; R1 Y R2 SON H, HALO, CF3, OR10, S(O)tR15, ENTRE OTROS; t ES 0-2; R3 Y R4 SON H, R1, R2; R5, R6, R7, SON H, CF3, COR10, ALQUILO, ARILO, ENTRE OTROS; R9 ES HETEROARILO, ARILALCOXI, HETEROCICLOALCOXI, ENTRE OTROS; R9a ARILO, ARILALQUILO. R10 ES H, ALQUILO, ARILO, ARILALQUILO; R15 ES ALQUILO, ARILO. LOS COMPUESTOS SE PUEDEN UTILIZAR CON QUIMIOTERAPICOS O RADIACION COMO MOSTAZA DE URACILO, CLORMETINA, CICLOFOSFAMIDA, IFOSFAMIDA, PIPOBROMAN, COLCHICINA, PACLITAXEL, EPOLTIONA, GEMCITABINA, ENTRE OTROS. LOS COMPUESTOS INHIBEN A CELULAS QUE EXPRESAN ONCOGEN DE RAS ACTIVADO POR INHIBICION DE LA FARNESIL TRANSFERASA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE CANCER DE PULMON, PANCREATICO, COLON, LEUCEMIA MIELOIDE, FOLICULAR TIROIDEO, VEJIGA GLIOMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22918300P | 2000-08-30 | 2000-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020486A1 true PE20020486A1 (es) | 2002-06-14 |
Family
ID=22860141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000865A PE20020486A1 (es) | 2000-08-30 | 2001-08-28 | Compuestos triciclicos como inhibidores de la farnesil proteino transferasa |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020198216A1 (es) |
| EP (1) | EP1313725B1 (es) |
| JP (1) | JP2004513885A (es) |
| KR (1) | KR20030034161A (es) |
| CN (1) | CN100384837C (es) |
| AR (1) | AR033680A1 (es) |
| AT (1) | ATE359281T1 (es) |
| AU (2) | AU2001288451C1 (es) |
| BR (1) | BR0113675A (es) |
| CA (1) | CA2420673A1 (es) |
| CO (1) | CO5640109A2 (es) |
| DE (1) | DE60127846T2 (es) |
| EC (1) | ECSP034494A (es) |
| ES (1) | ES2284686T3 (es) |
| HK (1) | HK1054548B (es) |
| HU (1) | HUP0302942A3 (es) |
| IL (1) | IL154528A0 (es) |
| MX (1) | MXPA03001849A (es) |
| NO (1) | NO20030918L (es) |
| NZ (1) | NZ524246A (es) |
| PE (1) | PE20020486A1 (es) |
| PL (1) | PL361103A1 (es) |
| RU (1) | RU2293734C9 (es) |
| SK (1) | SK2292003A3 (es) |
| TW (1) | TWI268280B (es) |
| WO (1) | WO2002018368A1 (es) |
| ZA (1) | ZA200301545B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) * | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| EP1383490B1 (en) * | 2001-03-14 | 2012-04-25 | Bristol-Myers Squibb Company | Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases |
| WO2003030908A2 (en) * | 2001-10-09 | 2003-04-17 | The University Of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
| CN1617755A (zh) * | 2001-11-30 | 2005-05-18 | 先灵公司 | 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 |
| CA2468996A1 (en) * | 2001-12-03 | 2003-06-12 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| JP4921965B2 (ja) * | 2003-03-27 | 2012-04-25 | ランケナー インスティテュート フォー メディカル リサーチ | 癌治療新規方式 |
| JP2006526662A (ja) * | 2003-06-05 | 2006-11-24 | アシュカル，チャールズ | 過増殖性細胞疾患を治療する方法 |
| CN1972712A (zh) * | 2003-06-09 | 2007-05-30 | 塞缪尔·瓦克萨尔 | 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法 |
| ES2235611B2 (es) * | 2003-07-25 | 2006-07-16 | Universidade De Santiago De Compostela | Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas. |
| AU2004263493A1 (en) | 2003-08-07 | 2005-02-17 | Schering Corporation | Novel farnesyl protein transferase inhibitors as antitumor agents |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| EP1831200A2 (en) * | 2004-12-21 | 2007-09-12 | Schering Corporation | Novel farnesyl protein transferase inhibitors as antitumor agents |
| RU2361587C1 (ru) * | 2008-02-14 | 2009-07-20 | Михаил Владимирович Кутушов | Лекарственное средство для лечения онкологических заболеваний |
| CA2730190A1 (en) * | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| CN114025751A (zh) * | 2019-06-28 | 2022-02-08 | 安徽荣航生物科技发展有限责任公司 | 用于治疗乙型肝炎病毒感染的组合物和方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| NZ238629A (en) * | 1990-06-22 | 1993-09-27 | Schering Corp | Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| PE92098A1 (es) * | 1996-07-31 | 1998-12-31 | Schering Corp | N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo |
| US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| US5925648A (en) * | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| KR20010081115A (ko) * | 1998-12-18 | 2001-08-27 | 둘락 노먼 씨. | 파르네실 단백질 트랜스퍼라제 억제제 |
-
2001
- 2001-08-27 AR ARP010104082A patent/AR033680A1/es unknown
- 2001-08-28 HK HK03105016.6A patent/HK1054548B/en not_active IP Right Cessation
- 2001-08-28 MX MXPA03001849A patent/MXPA03001849A/es active IP Right Grant
- 2001-08-28 TW TW090121201A patent/TWI268280B/zh active
- 2001-08-28 ES ES01968188T patent/ES2284686T3/es not_active Expired - Lifetime
- 2001-08-28 AU AU2001288451A patent/AU2001288451C1/en not_active Ceased
- 2001-08-28 IL IL15452801A patent/IL154528A0/xx unknown
- 2001-08-28 PL PL01361103A patent/PL361103A1/xx unknown
- 2001-08-28 SK SK229-2003A patent/SK2292003A3/sk not_active Application Discontinuation
- 2001-08-28 WO PCT/US2001/026792 patent/WO2002018368A1/en not_active Ceased
- 2001-08-28 CA CA002420673A patent/CA2420673A1/en not_active Abandoned
- 2001-08-28 EP EP01968188A patent/EP1313725B1/en not_active Expired - Lifetime
- 2001-08-28 AT AT01968188T patent/ATE359281T1/de not_active IP Right Cessation
- 2001-08-28 DE DE60127846T patent/DE60127846T2/de not_active Expired - Fee Related
- 2001-08-28 AU AU8845101A patent/AU8845101A/xx active Pending
- 2001-08-28 KR KR10-2003-7003012A patent/KR20030034161A/ko not_active Ceased
- 2001-08-28 PE PE2001000865A patent/PE20020486A1/es not_active Application Discontinuation
- 2001-08-28 HU HU0302942A patent/HUP0302942A3/hu unknown
- 2001-08-28 CN CNB01818121XA patent/CN100384837C/zh not_active Expired - Fee Related
- 2001-08-28 RU RU2003108865/04A patent/RU2293734C9/ru not_active IP Right Cessation
- 2001-08-28 JP JP2002523486A patent/JP2004513885A/ja active Pending
- 2001-08-28 US US09/940,811 patent/US20020198216A1/en not_active Abandoned
- 2001-08-28 NZ NZ524246A patent/NZ524246A/en unknown
- 2001-08-28 BR BR0113675-5A patent/BR0113675A/pt not_active IP Right Cessation
-
2003
- 2003-02-25 ZA ZA200301549A patent/ZA200301545B/xx unknown
- 2003-02-26 EC EC2003004494A patent/ECSP034494A/es unknown
- 2003-02-27 CO CO03017118A patent/CO5640109A2/es active IP Right Grant
- 2003-02-27 NO NO20030918A patent/NO20030918L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020486A1 (es) | Compuestos triciclicos como inhibidores de la farnesil proteino transferasa | |
| CY1106125T1 (el) | Ενωσεις πυρρολινης υποκατεστημενες με ινδαζολυλιο ως αναστολεις κινασης | |
| CO5180568A1 (es) | Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen | |
| AR022323A1 (es) | Complejo del inhibidor de ras-farnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y composiciones formuladas condicho complejo | |
| ATE259826T1 (de) | Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase | |
| ES2112140B1 (es) | 3-arilbenzofuranonas como estabilizantes | |
| CY1109441T1 (el) | Ενδιαμεσα προϊοντα για την παραγωγη διοξανιου-2-αλκυλκαρβαμικου | |
| DE69401658D1 (de) | Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese | |
| ATE524522T1 (de) | Xanthen-farbstoffe | |
| PE20001516A1 (es) | Compuestos triciclicos como inhibidores de la farnesil transferasa | |
| ES2044013T3 (es) | Compuesto mesomorfico, una composicion de cristal liquido que contiene el compuesto y un dispositivo de cristal liquido que utiliza la composicion. | |
| CO4900071A1 (es) | Derivados de pirido [4´, 3´:4,5] tieno (2,3- d) pirimidina sustituidos en posicion 3 | |
| CO4700523A1 (es) | Purin-6-onas bisustituidas en 2,9 | |
| ES2174781T3 (es) | Articulo coextruido de resina de policarbonato. | |
| DE60229054D1 (de) | Synthese von zyklopentadien derivaten | |
| CO5690604A2 (es) | Derivados de [6,7-dihidro-5h-imidazo[1.2-alfa]imidazol-3- sulfonilamino]-propionamida | |
| DK1021421T3 (da) | Amino- og hydroxy-substituerede triphenyl-S-triaziner som stabilisatorer | |
| PE20001342A1 (es) | Compuestos triciclicos como inhibidores de farnesil transferasa | |
| TW200704653A (en) | Ultraviolet absorbing polymer for high light resistant recording materials | |
| CY1107287T1 (el) | Χρηση της ερυθροποιητινης, καθως και παραγωγων αυτης για τη θεραπεια σχιζοφρενειων και συναφων ψυχωσεων | |
| ES2066187T3 (es) | Compuestos de fosforo. | |
| ES475588A1 (es) | Procedimiento para la obtencion de derivados del acido inde-no -2,1-b- tiofen-2-oxamico | |
| PE20030197A1 (es) | Derivados de pirrol heteroarilo-substituidos como inhibidores de la produccion de citosinas inflamatorias | |
| CY1105972T1 (el) | ΝΕΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ [1,4] ΒΕΝΖΟΔΙΟΞΙΝΟ [2,3-e] ΙΣΟΪΝΔΟΛΙΟΥ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΑΥΤΩΝ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΑ ΠEPΙΕΧΟΥΝ | |
| ES485927A1 (es) | Un procedimiento para la produccion de un derivado de feno- xialqueno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |